POPULARITY
Categories
148 episodes with responses
31 episodes with responses
32 episodes with responses
28 episodes with responses
42 episodes with responses
40 episodes with responses
24 episodes with responses
23 episodes with responses
34 episodes with responses
18 episodes with responses
16 episodes with responses
34 episodes with responses
98 episodes with responses
13 episodes with responses
17 episodes with responses
8 episodes with responses
7 episodes with responses
8 episodes with responses
19 episodes with responses
8 episodes with responses
6 episodes with responses
5 episodes with responses
13 episodes with responses
17 episodes with responses
6 episodes with responses
12 episodes with responses
10 episodes with responses
9 episodes with responses
4 episodes with responses
5 episodes with responses
5 episodes with responses
8 episodes with responses
6 episodes with responses
3 episodes with responses
5 episodes with responses
7 episodes with responses
12 episodes with responses
4 episodes with responses
5 episodes with responses
5 episodes with responses
5 episodes with responses
13 episodes with responses
4 episodes with responses
4 episodes with responses
7 episodes with responses
4 episodes with responses
5 episodes with responses
7 episodes with responses
7 episodes with responses
6 episodes with responses
4 episodes with responses
6 episodes with responses
3 episodes with responses
5 episodes with responses
3 episodes with responses
6 episodes with responses
8 episodes with responses
4 episodes with responses
7 episodes with responses
6 episodes with responses
6 episodes with responses
5 episodes with responses
3 episodes with responses
4 episodes with responses
6 episodes with responses
6 episodes with responses
6 episodes with responses
5 episodes with responses
5 episodes with responses
10 episodes with responses
7 episodes with responses
5 episodes with responses
4 episodes with responses
7 episodes with responses
3 episodes with responses
2 episodes with responses
3 episodes with responses
4 episodes with responses
6 episodes with responses
9 episodes with responses
8 episodes with responses
2 episodes with responses
3 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
3 episodes with responses
5 episodes with responses
4 episodes with responses
3 episodes with responses
4 episodes with responses
4 episodes with responses
5 episodes with responses
4 episodes with responses
4 episodes with responses
6 episodes with responses
2 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
5 episodes with responses
5 episodes with responses
2 episodes with responses
8 episodes with responses
6 episodes with responses
3 episodes with responses
3 episodes with responses
6 episodes with responses
5 episodes with responses
4 episodes with responses
5 episodes with responses
4 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
4 episodes with responses
6 episodes with responses
2 episodes with responses
4 episodes with responses
4 episodes with responses
5 episodes with responses
4 episodes with responses
2 episodes with responses
3 episodes with responses
3 episodes with responses
6 episodes with responses
4 episodes with responses
3 episodes with responses
9 episodes with responses
4 episodes with responses
4 episodes with responses
5 episodes with responses
2 episodes with responses
3 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
6 episodes with responses
2 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
7 episodes with responses
7 episodes with responses
7 episodes with responses
2 episodes with responses
4 episodes with responses
3 episodes with responses
3 episodes with responses
3 episodes with responses
4 episodes with responses
4 episodes with responses
4 episodes with responses
4 episodes with responses
4 episodes with responses
5 episodes with responses
5 episodes with responses
5 episodes with responses
5 episodes with responses
3 episodes with responses
2 episodes with responses
3 episodes with responses
3 episodes with responses
5 episodes with responses
3 episodes with responses
2 episodes with responses
4 episodes with responses
6 episodes with responses
2 episodes with responses
4 episodes with responses
4 episodes with responses
The Strawberry Letter heard on The Steve Harvey Morning Show Thursday, May 22nd, 2025: "I'm Surprised By What I Found In His Car" A woman found a key, a garage remose, new underwear, and extra clothes in her husband's car and she's got questions. Listen to hear the letter and Steve & Shirley's Responses!See omnystudio.com/listener for privacy information.
Jackson "Pinkie" Pinkoski is back on the show, and he and Mike dive into the power of email marketing for cleaning business owners. They share why overthinking your emails is killing your momentum — and how short, consistent messages win every time. You'll learn the difference between evergreen and seasonal emails, and why one email won't change your business — but 20 might. Mike also dishes out tips on keeping it simple, clear, and action-focused. If you've been stuck with “blank page syndrome,” this episode is your kickstart. Tune in and start writing emails that actually work! Love the idea, but find it overwhelming? Want to learn the next steps like, what to actually say on the call? Jump on a call with one of our coaches and learn strategies on how to grow your cleaning company and start loving your job every day! Book here
Got some great d-bag responses.
The Evidence Based Chiropractor- Chiropractic Marketing and Research
This week, we're diving into a fascinating new study exploring the neuromuscular responses to spinal adjustments. Dr. Langmaid breaks down the latest research, published in January 2025, which pulls insights from over 35 studies to reveal what really happens in the body—from muscle activation and reflex changes to cortical (brain) responses—after a chiropractic adjustment.If you've ever wondered how chiropractic care impacts the body beyond just pain relief, this episode is packed with data and actionable insights you can use in practice. Episode Notes: Neuromuscular Response to High-Velocity, Low-Amplitude Spinal Manipulation—An OverviewThe Best Objective Assessment of the Cervical Spine- Provide reliable assessments and exercises for Neuromuscular Control, Proprioception, Range of Motion, and Sensorimotor-Integration. Learn more at NeckCare.comTurncloud EHR- Minimalist design, without being sparse. Practical, yet elegant. Turncloud's design was to find the most efficient path in a day in the life of a chiropractic office. Connect with their team at www.turncloud.com Patient Pilot by The Smart Chiropractor is the fastest, easiest to generate weekly patient reactivations on autopilot…without spending any money on advertising. Click here to schedule a call with our team.Our members use research to GROW their practice. Are you interested in increasing your referrals? Discover the best chiropractic marketing you aren't currently using right here!
In Episode 276, Kyle kicks things off with a brunch story involving an oversized, impossible-to-handle coffee mug and a series of well-intentioned but clumsy attempts to make it right.The episode then shifts gears with a fun and thought-provoking compilation of answers from past guests to the question: If you ruled the world, what would you change? Responses range from practical ideas like increasing accessibility and reducing barriers, to grand visions of kindness, open science, and even perfect weather in Pennsylvania. Each guest's answer serves as a reminder of how personal experiences shape our view of what the world could be.The episode wraps up with heartfelt thank-you notes: Kyle expresses his gratitude to all his generous donors by adding each of their names to his fundraising “spirit chain,” while Sean thanks Santino, a colleague who went out of his way to share how much he enjoyed Sean's recent corporate presentation. These moments of appreciation highlight the power of connection and acknowledgment in both personal and community-driven efforts.This episode is a reminder that even small gestures can have a world-changing impact.Links and ResourcesKatie, Team TelomereHeidi, Association for Creatine Deficiencies (ACD)Jay, Write on, Fight onRivki, CTNNB1 Connect & CureKendall, IconErin, Rea of Hope
Finding Jesus in Unexpected Places - Asleep in the Boat Mark 4:35-41 (NIV)“That day when evening came, he said to his disciples, ‘Let us go over to the other side.' Leaving the crowd behind, they took him along, just as he was, in the boat. There were also other boats with him. A furious squall came up, and the waves broke over the boat, so that it was nearly swamped. Jesus was in the stern, sleeping on a cushion. The disciples woke him and said to him, ‘Teacher, don't you care if we drown?' He got up, rebuked the wind and said to the waves, ‘Quiet! Be still!' Then the wind died down and it was completely calm. He said to his disciples, ‘Why are you so afraid? Do you still have no faith?' They were terrified and asked each other, ‘Who is this? Even the wind and the waves obey him!'” 1. Jesus says to them, “Let's go over to the other side…” 1 John 4:17-18 (ESV)By this is love perfected with us, so that we may have confidence for the day of judgment, because as he is so also are we in this world. There is no fear in love, but perfect love casts out fear. For fear has to do with punishment, and whoever fears has not been perfected in love. 2. Responses to Fear in Life.1. Evasion2. Control3. Engagement4. Faith Hebrews 11:1 (NIV) “Now faith is being sure of what we hope for and certain of what we do not see.”
Summary Dr. David Rosenblum delivered a comprehensive lecture on gender differences in opiate effects and prescribing practices. He discussed several key studies examining how opiates affect males and females differently, both in animal models and humans. Dr. Rosenblum shared findings showing that morphine has stronger analgesic effects in males, while females experience longer-lasting effects. He also addressed racial disparities in opiate prescribing, noting that white patients are more likely to receive opiates. From his personal clinical experience in Brooklyn, Dr. Rosenblum observed that certain populations tend to be at higher risk for opiate abuse. The lecture covered gender-specific risk factors for opiate misuse, with women tending toward emotional/psychological factors and men showing more behavioral issues. Pain Management Board Prep Ultrasound Training REGISTER TODAY! Chapters Introduction and Upcoming Conferences Dr. Rosenblum introduced himself as the host of the Pain Exam Podcast and announced several upcoming conferences including ASPN in July, PainWeek in September, and other events where he will be teaching ultrasound and regenerative medicine. Board Preparation and Opiate Topics Dr. Rosenblum discussed his role in board preparation through painxam.com and nreppain.org. He emphasized that opiates are a frequently tested topic across different board examinations (FIP, ABPM, ABIP, ABA). Gender Differences in Opiate Effects - Animal Studies Dr. Rosenblum presented research showing that in animal studies, morphine exhibited stronger analgesic effects in males, while females showed longer-lasting effects and could tolerate higher doses. He noted that physical dependence was more severe in male rats during spontaneous withdrawal. Racial and Gender Disparities in Opiate Prescribing Dr. Rosenblum discussed a 2025 study revealing racial disparities in opiate prescribing, with white patients more likely to receive opiates. He shared his personal clinical experience in Brooklyn, noting that young white males were often higher-risk for abuse. Gender-Specific Risk Factors for Opiate Misuse Dr. Rosenblum detailed how women tend to show emotional and psychological risk factors for opiate misuse, while men demonstrate more behavioral risk factors. Women were more likely to report distress and past trauma, while men showed higher rates of criminal behavior and substance abuse history. References Djurendic-Brenesel, Maja, et al. "Gender-related differences in the pharmacokinetics of opiates." Forensic science international 194.1-3 (2010): 28-33. Kosten, Thomas R., Bruce J. Rounsaville, and Herbert D. Kleber. "Ethnic and gender differences among opiate addicts." International Journal of the Addictions 20.8 (1985): 1143-1162. Cicero, Theodore J., Shawn C. Aylward, and Edward R. Meyer. "Gender differences in the intravenous self-administration of mu opiate agonists." Pharmacology Biochemistry and Behavior 74.3 (2003): 541-549. Jamison, Robert N., et al. "Gender differences in risk factors for aberrant prescription opioid use." The Journal of Pain 11.4 (2010): 312-320.
Preview: Colleague Bob Zimmerman reports on the extended life of Voyager 1. More.
Trent Horn of the Counsel of Trent channel asks a question that he claims atheists can't answer. So I answer it.Cards:Proof of Not God? An Atheist Claims to Falsify God:www.youtube.com/watch?v=LszC4yJa1X0Did Rhett Just Break Christianity on Resurrection Sunday? (Responding to ALL the Responses):https://www.youtube.com/watch?v=2onIdSbqSRQOriginal Video: https://tinyurl.com/28vemls3Sources: Rational, Normative, Descriptive, Prescriptive, or Choice Behavior? The Search for Integrative Metatheory of Decision Making: https://tinyurl.com/272yl28mAll my various links can be found here:http://links.vicedrhino.comThis content is CAN credentialed, which means you can report instances of harassment, abuse, or other harm on their hotline at (617) 249-4255, or on their website at creatoraccountabilitynetwork.orgBecome a supporter of this podcast: https://www.spreaker.com/podcast/viced-rhino-the-podcast--4623273/support.
When we see our kids struggling with things like schoolwork, or friend drama, or dealing with a teacher they don't like, we often offer suggestions to help them get through those situations more easily. But what should we do when our children give short or snarky responses to our genuine attempts to help? In this episode, you'll learn: Why kids are so resistant to our suggestions, even if they know they're good ones What we almost always do that makes the situation worse How to respond to this type of attitude so that you maintain your positive, powerful influence (and they don't get away with anything!) -- Join the "Daily Lift" for $1 Free summary of (and examples from) this episode Join Rachel's Facebook group The Leadership Parenting Academy and Success Lab
Got some great responses on todays d-bag?
Through the darkness of future past, the magician longs to see. One chants out between two worlds... fire walk with me.When David Lynch's megahit series Twin Peaks was cancelled after two seasons, people eagerly awaited the announced feature film. Responses were decidedly mixed, however, on the finished film, controversial as it was for missing lots of key series regulars and for focusing almost exclusively on the last week of Laura Palmer's life. Despite an outstanding performance from Sheryl Lee and Lynch's signature stylistic flourishes, Fire Walk with Me was greeted with mostly negative feedback.This week, we continue our Lynch series by revisiting that film and trying to uncover its value in light of its subject matter. We're joined by friend of the show Steven Beckley and feature a Patron-only segment featuring a chat between Reed and Nathan about episodes 8 & 9. Whether you've been following our chats from the beginning or whether this is your biggest prompt yet to do so, we hope you enjoy this look at "who killed Laura Palmer" and the legacy of Twin Peaks.Patron Only Segment: Twin Peaks, Season 2, Episodes 8 & 94:41 - TWIN PEAKS: FIRE WALK WITH MESee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.
Emotional Triggers can pull you down. Take back your power! Do you need help responding to lewd or disrespectful things men say? In this "When He" episode Adrienne & Natalina discuss how to stay in Feminine Energy alignment despite upsetting words or behaviors.Get coaching & support in my private group iHeartLoveAcademy! xoxo,Adrienne♡~♡~♡~♡~♡~♡~ Bonus Links ~♡~♡~♡~♡~♡~♡Youtube:@AdrienneEverheartGet Courses & More at https://everheartcoaching.comExplore my Private Coaching Community https://iheartloveacademy.mn.coFollow Me on InstagramLIKE me on Facebook
Send us a textDr. Samir Khleif, MD is CEO of Georgiamune ( https://www.georgiamune.com/team ), a private, science and discovery clinical stage immunotherapeutic biotechnology company focused on reprogramming immune signaling pathways to redirect the immune system to fight diseases. Dr. Khleif is a pioneer in the field of immunotherapy. He is a medical oncologist, immunologist, innovator, and entrepreneur, as well as a transformational executive in health care and biomedical research.Prior to becoming CEO of Georgiamune, Dr. Khleif served in different academic and leadership positions. He was a National Cancer Institute (NCI)/National Institutes of Health (NIH) scientist and Chief of the NCI Cancer Vaccine Section, where he led the development of pioneering immune-oncology and cancer vaccines into clinical trials. As a national and international academic leader, and detailed by the US government, he served as the founding director and CEO of the King Hussein Cancer Center ( https://www.khcc.jo/en ) in Amman, Jordan, where he led the development of the largest cancer center in the MENA region. He also served as the director of the Georgia Cancer Center, the state cancer center, at Augusta University. He is currently a biomedical scholar and holds a professorship at Georgetown University Medical School.Dr. Khleif also served as a Special Assistant to the Commissioner of the FDA, leading the FDA's Critical Path Initiative for Oncology. He is a member of the board of directors of Ayala Pharmaceuticals and Emerald Biopharmaceutics, and served as a member of the scientific advisory board of more than 20 biotechnology and pharmaceutical companies.Dr. Khleif is an international KOL in immunology and immunotherapy. He has served on many national committees, including the Scientific Advisory Board of the Biden Cancer Initiative, as chair of the Immunotherapy Committee for NRG, and as a member of the NCI Cooperative Group. He currently serves as an advisor for the Parker Institute for Cancer Immunotherapy. Dr. Khleif is an editor of three books, the author of hundreds of peer-reviewed scientific research articles, and a prolific inventor with more than 150 patents issued or pending in the field of immunology and immunotherapy.Dr. Khleif received his medical degree at the University of Jordan, Amman Jordan. He completed his residency in Internal Medicine at the Medical College of Ohio and his fellowship in Medical Oncology at the National Cancer Institute (NCI) in Bethesda, Maryland.#SamirKhleif #Georgiamune #Immunotherapy #KingHusseinCancerCenter #CriticalPathInitiative #FDA #Tregs #RegulatoryTCells #Cancer #Oncology #CheckpointInhibitors #ImmuneEscapeMechanisms #DualFunctioningAntibody #Autoimmune #ProgressPotentialAndPossibilities #IraPastor #Podcast #Podcaster #Podcasting #ViralPodcast #STEM #Innovation #Science #Technology #ResearchSupport the show
Glenn Robbins joins Ross and Russ every Tuesday morning for a bit of fun in the studio!See omnystudio.com/listener for privacy information.
Message from Katie Larsen on May 11, 2025
Do you have a partner or friend that exhibits some of the signs of an avoidant attachment style?And do you find your own anxiety being triggered by their behaviour - resulting in a push-pull cycle - where both people feel frustrated and disconnected?You're certainly not alone with this.And in today's episode, I'm teaching you how to manage your OWN mind and create a secure response to avoidant behaviour.So that you can feel calm and grounded, regardless of what's going on for them - and actually create more connection.Mentioned in this episode:SIGN UP TO THE 5 DAY CHALLENGEProcessing emotions meditationSelf Esteem Building KitEmail me about 1:1 coaching - rebecca@rebeccaorecoaching.com
Today the word "Christian" is polarizing. In fact for many it conjures up words like hate, nationalism, evil, fear. WOW...it should not. Then couple that word with Queer, and you might as well be burned at the stake! Let's not do that. Instead, let's invite Queer Christians to the table to embrace their love of goad and faith, and invite others who do not believe you deserve a place at the table, to have human conversations to change that hate, to love. Repeat podcast guest, Rev. Brandan Robertson joins us today to share his new book Queer and Christian: Reclaiming The Bible, Faith, Our Faith, and Our place At The Table - a joyful celebration of queer faith. In this episode: Discover calm, peaceful, empathetic conversations with the extreme Christians are necessary Learn why coming to church is an act of community and activism Uncover the right questions to ask to reclaim your faith in yourself and your community About Brandan Rev. Brandan Robertson is a noted author, activist, and public theologian, dedicated to exploring the intersections of spirituality, sexuality, and social justice. He serves as the Pastor of Sunnyside Reformed Church in New York City and is the founder and Executive Director of The Devout Foundation. Known as the "TikTok Pastor," Robertson's inclusive theological content reaches over 250,000 followers and has garnered 6 million views. He has authored 23 books, including the INDIES Book of the Year finalist True Inclusion. His work has been featured in TIME Magazine, CNN, and The Washington Post. Robertson is a sought-after speaker who regularly presents at prestigious platforms like The White House and Oxford University, continuing to inspire and challenge audiences around the world. Robertson acquired a Bachelor of Arts in Pastoral Ministry and Biblical Studies from Moody Bible Institute, an Master of Theological Study from Iliff School of Theology, and an Master of Arts in Political Science and Public Administration from Eastern Illinois University. He's presently pursuing aPhD in Biblical Studies at Drew University. He currently resides in New York City. About The Book Celebrate queer faith and take your rightful place at God's table with Brandan Robertson, the “TikTok Pastor,” Biblical scholar, and social activist For too long, the Bible has been weaponized to exclude LGBTQ+ individuals, despite Jesus' radical message of inclusion. In Queer & Christian, Brandan Robertson envisions a faith where all are unequivocally embraced. Ostracized at school, Brandan thought he had finally found his community when he joined the local church. But he soon realized that they were as intolerant as his peers at school had been—if not more so. After agonizing years of repressing his true identity, he discovered that God's table had always had a place for him. Jesus' love knows no bounds, embracing everyone unconditionally. Queer & Christian is a joyful celebration of queer faith and an unyielding reclamation of the Bible. Dive into pages that offer: -Compelling, evidence-based counterarguments to the “clobber verses” often used to condemn queerness -Celebrations of queer saints within the Bible—more numerous than you might believe! -Responses to commonly asked questions by queer folks and allies who're feeling lost within the Christian faith Connect With Brandan Website Instagram TikTok Hey Guys, Check This Out!...
Good evening: The show begins in Kashmir, measuring the fog of war..... 1948 CBS EYE ON THE WORLD WITH JOHN BATCHELOR FIRST HOUR 9:00-9:15 #Kashmir: Escalation. Colonel Jeff McCausland, USA (Retired) @McCauslJ @CBSNews @DickinsonCol 9:15-9:30 #Yemen: Escalating. Colonel Jeff McCausland, USA (Retired) @McCauslJ @CBSNews @DickinsonCol 9:30-9:45 #Kashmir: Terror Camps. Bill Roggio, FDD 9:45-10:00 #Russia: Sinking Price of Oil. Michael Bernstam, Hoover SECOND HOUR 10:00-10:15 #Taiwan: Ever Threatened. Gerrit van der Wees, adjunct professor at George Washington University's Elliott School of Foreign Affairs and George Mason University Schar School of Government 10:15-10:30#PRC: Dead Cat. Andrew Collier, managing director of Orient Capital Research and author of new book, "China's Technology War: Why Beijing Took Down Its Tech Giants," @GordonGChang, Gatestone, Newsweek, The Hill 10:30-10:45 #Losing Aircraft. Rebecca Grant, vice president of the Lexington Institute 10:45-11:00 #Losing Nimitz. James Fanell, co-author of "Embracing Communist China: America's Greatest Strategic Failure" and government fellow at the Geneva Centre for Security Policy THIRD HOUR 11:00-11:15 #NewWorldReport: Venezuela Rescue. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @REvanEllis #NewWorldReportEllis 11:15-11:30 #NewWorldReport: Best Investment 2025. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @REvanEllis #NewWorldReportEllis 11:30-11:45 #NewWorldReport: Surinam Rising. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @REvanEllis #NewWorldReportEllis 11:45-12:00 #NewWorldReport: Murder in Peru. Latin American Research Professor Evan Ellis, U.S. Army War College Strategic Studies Institute. @REvanEllis #NewWorldReportEllis FOURTH HOUR 12:00-12:15 #EU: Lights Out Spain and Portugal. Simon Constable, Occitanie 12:15-12:30 #France: Ex-Patriotism Means Lots of Paper. Simon Constable, Occitanie 12:30-12:45 #SpaceX: Starbase, TX. Bob Zimmerman, BehindTheBlack.com 12:45-1:00 AM #Pulsar: At The Core. Bob Zimmerman, BehindTheBlack.com
SEND US A TEXT MESSAGE Ever feel like your body is calm—but your mind is still bracing for impact? In this eye-opening episode, we explore what's really running the show when stress, anxiety, and emotional shutdown hijack our lives—no matter how much therapy, mindset work, or self-talk we've done. Our guest, Natalie Baker, is a psychotherapist and neurofeedback expert who blends Eastern wisdom with cutting-edge brain science to help clients rewire the patterns keeping them stuck in survival mode. Natalie breaks down how neurofeedback gives your brain real-time feedback so it can stop reacting to old threats and start responding to the present moment. From helping high performers manage anxiety to guiding trauma survivors back to inner calm, Natalie shares how this powerful tool helps people finally step out of autopilot and into a regulated, resilient life. Whether you're an entrepreneur battling burnout, a parent navigating emotional landmines, or someone who's done all the “right” things and still feels stuck—this conversation will give you both hope and a new lens on healing. ✍️ WORKBOOK MOMENTS: Use these prompts to journal, reflect, or open up a deeper conversation: When does your body feel triggered, even when you know you're safe? What emotional “loop” do you keep falling into—despite all your efforts to change? What belief or pattern might your brain be clinging to for survival? How do you cope when your nervous system says “danger” but your mind says “you're fine”? What would your life feel like if you could respond from the present instead of reacting from the past? Connect with Natalie: Website: www.neurofeedbacktraining.com Instagram: https://www.instagram.com/neurofeedbacktrainingco/ Facebook: https://www.facebook.com/NeurofeedbackNY/ Youtube: https://www.youtube.com/@Neurofeedbacktraining Connect With Us:
Chris Edmonds teaches the Faith Church congregation on Wednesday night, May 7, 2025. This is week 10 of his series on the book of John titled "These Are Written". This is part 1 of his message titled "More Signs, Mixed Responses" and it comes from John 5 & 6.
Host Dr. Davide Soldato and guest Dr. Harriet Kluger discuss the JCO article "Phase II Trial of Pembrolizumab in Combination With Bevacizumab for Untreated Melanoma Brain Metastases." Transcript The guest on this podcast episode has no disclosures to declare. Dr. Davide Soldato Hello and welcome to JCO After Hours, the podcast where we sit down with authors from some of the latest articles published in the Journal of Clinical Oncology. I am your host, Dr. Davide Soldato, Medical Oncologist at Ospedale San Martino in Genoa, Italy. Today, we are joined by JCO author Dr. Harriet Kluger. Dr. Kluger is a professor of medicine at Yale School of Medicine, Director of the Yale SPORE in Skin Cancer, and an internationally recognized expert in immuno-oncology for melanoma and renal cell carcinoma. She leads early-phase and translational trials that pair novel immunotherapies with predictive biomarkers to personalized care. Today, Dr. Kluger and I will be discussing the article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases." In this study, Dr. Kluger and colleagues evaluated four cycles of pembrolizumab plus the anti-VEGF antibody bevacizumab followed by pembrolizumab maintenance in patients with asymptomatic non-hemorrhagic melanoma brain metastases that had not previously received PD-1 therapy. Thank you for speaking with us, Dr. Kluger. Dr. Harriet Kluger Thank you for inviting me. The pleasure is really all mine. Dr. Davide Soldato So to kick off our podcast, I just wanted to ask if you could outline a little bit the biological and clinical rationale that led you to test this type of combination for patients with untreated brain metastases from metastatic melanoma. Dr. Harriet Kluger Back in approximately 2012, patients who had untreated brain metastases were excluded from all clinical trials. So by untreated, I mean brain metastases that had not received local therapy such as surgery or radiation. The reason for it was primarily because there was this fear that big molecules wouldn't penetrate brain lesions because they can't pass the blood-brain barrier. Turns out that the blood-brain barrier within a tumor is somewhat leaky and drugs sometimes can get in there. When PD-1 inhibitors were first identified as the next blockbuster class of drugs, we decided to conduct a phase 2 clinical trial of pembrolizumab monotherapy in patients with untreated brain metastases. We actually did it also in lung cancer, and we could talk about that later on. Responses were seen. The responses in the brain and the body were similar. They were concordant in melanoma patients. Now, at approximately that time, also another study was done by the Australian group by Dr. Georgina Long, where they did a randomized trial where patients who didn't require immediate steroid therapy received either nivolumab alone or nivolumab with ipilimumab, and the combination arm was substantially superior. Subsequently, also, Bristol Myers Squibb also conducted a large phase 2 multicenter trial of ipilimumab and nivolumab in patients with untreated brain metastases. And there, once again, they saw that the responses in the brain were similar to the responses in the body. Now, somewhere along the line there, we completed our anti-PD-1 monotherapy trial. And when we looked at our data, we still didn't have the data on ipilimumab and nivolumab. And our question was, “Well, how can we do better?” Just as we're always trying to do better. We saw two really big problems. One was that patients had a lot of perilesional edema. And the other one was that we were struggling with radiation necrosis in lesions that were previously Gamma Knifed. The instance of radiation necrosis was in excess of 30%. So the rationale behind this study was that if we added bevacizumab, maybe we could treat those patients who had some edema, not requiring steroids, but potentially get them on study, get that PD-1 inhibitor going, and also prevent subsequent radiation necrosis. And that was the main rationale behind the study. We had also done some preclinical work in mouse models of melanoma brain metastases and in an in vitro blood-brain barrier model where we showed that bevacizumab, or anti-VEGF, really tightens up those leaky basement membranes and therefore would be very likely to decrease the edema. Dr. Davide Soldato Thank you very much for putting in context the combination. So this was a phase 2 trial, and you included patients who had at least one lesion, and you wanted lesions that were behind 5 and 20 millimeters. Patients could be included also if the brain metastasis was higher in dimension than 20 millimeters, but it had to be treated, and it was then excluded from the evaluation of the primary objective of the trial. So regarding, a little bit, these characteristics, do you think that this is very similar to what we see in clinical practice? And what does this mean in terms of applicability of these results in clinical practice? Dr. Harriet Kluger So that's an excellent question. The brain metastasis clinical research field has somewhat been struggling with this issue of inclusion/exclusion criteria. When we started this, we showed pretty clearly that 5 to 10 millimeter lesions, which are below the RECIST criteria for inclusion, are measurable if you use MRIs with slices that are 1 to 2 millimeters. Most institutions in the United States do use these high-resolution MRIs. I don't know how applicable that is on a worldwide scale, but we certainly lowered the threshold for inclusion so that patients who have a smattering of small brain metastases would be eligible. Now, patients with single large brain metastases, the reason that we excluded those from the trial was because we were afraid that if a patient didn't respond to the systemic therapy that we were going to give them, they could really then develop severe neurological symptoms. So, for patient safety, we used 20 millimeters as the upper level for inclusion. Some of the other trials that I mentioned earlier also excluded patients with very large lesions. Now, in practice, one certainly can do Gamma Knife therapy to the large lesions and leave the smaller ones untreated. So I think it actually is very applicable to clinical practice. Dr. Davide Soldato Thank you very much for that insight, because I think that sometimes criteria for clinical trials, they have to be very restrictive. But then we know that in clinical practice, the applicability of these results is probably broader. So, going a little bit further in the results of the study, I just wanted a little bit of comment from you regarding what you saw in terms of intracranial response rate and duration of response among patients who obtained a response from the combination treatment. Dr. Harriet Kluger So we were actually surprised. When we first designed this study, as I said earlier, we weren't trying to beat out ipilimumab and nivolumab. We were really just trying to exclude those patients who wouldn't have otherwise been eligible for ipilimumab and nivolumab because of edema or possibly even previous radiation necrosis. So it was designed to differentiate between a response rate of 34%, and I believe the lower bound was somewhere in the 20s, because that's what we'd seen in the previous pembrolizumab study. What we saw in the first 20 patients that we enrolled was actually a response rate that far exceeded that. And so we enrolled another cohort to verify that result because we were concerned about premature publishing of a result that we might have achieved just by chance. The two cohorts were very similar in terms of the response rates. And certainly this still needs to be verified in a second study with additional institutions. We did include the Moffitt Cancer Center, and the response rate with Moffitt Cancer Center was very similar to the Yale Cancer Center response rate. Now, your other question was about duration of response. So the other thing that we started asking ourselves was whether this high response rate was really because the administration of the anti-VEGF will decrease the gadolinium enhancement and therefore we might actually just be seeing prettier scans but not tumor shrinkage. And the way to differentiate those two is by looking at the duration of the response. Median progression-free survival was 2.2 years. That's pretty long. The upper bound on the 95% confidence interval was not reached. I can't tell you that the duration is as good as the duration would be when you give ipilimumab. Perhaps it is less good. This was a fairly sick population of patients, and it included some who might not have been able to receive ipilimumab and nivolumab. So it provides an alternative. I do believe that we need to do a randomized trial where we compare it to ipilimumab and nivolumab, which is the current standard of care in this patient population. We do need to interpret these results with caution. I also want to point out regarding the progression-free survival that we only gave four doses of anti-VEGF. So one would think that even though anti-VEGF has a long half-life of three or four weeks, two years later, you no longer have anti-VEGF effect, presumably. So it does something when it's administered fairly early on in the course of the treatment. Dr. Davide Soldato So, in terms of clinical applicability, do you see this combination of pembrolizumab and bevacizumab - and of course, as we mentioned, this was a phase 2 trial. The number of patients included was not very high, but still you saw some very promising results when compared with the combination of ipilimumab and nivolumab. So do you see this combination as something that should be given particularly to those patients who might not be able to receive ipilimumab and nivolumab? So, for example, patients who are very symptomatic from the start or require a high dose of steroids, or also to provide a quicker response in terms of patients who have neurological symptoms, or do you think that someday it could be potentially used for all patients? Dr. Harriet Kluger The third part of your question, whether it can be used someday for all patients: I think we need to be very careful when we interpret these results. The study was substantially smaller than the ipilimumab/nivolumab trial that was conducted by Bristol Myers Squibb. Also going to point out that was a different population of patients. Those were all frontline patients. Here we had a mix of patients who'd had previous anti-CTLA-4 and frontline patients. So I don't think that we can replace ipilimumab and nivolumab with these results. But certainly the steroid-sparing aspect of it is something that we really need to take into consideration. A lot of patients have lesions in locations where edema can be dangerous, and some of them have a hard time coming off the steroids. So this is certainly a good approach for those folks. Dr. Davide Soldato And coming back to something that you mentioned in the very introduction, when you said that there were two main problems, which was one, the problem of the edema, and the second one, the problem of the radionecrosis. In your trial, there was a fair percentage of patients who received some type of local treatment before the systemic one. So the combination of pembrolizumab and bevacizumab. And most of the patients received radiosurgery. So I just wanted a brief comment regarding the incidence of radionecrosis in the trial and whether that specific component of the combination with bevacizumab was reduced. And how do you think that this fares in terms of what we see in clinical practice in terms of radionecrosis? Dr. Harriet Kluger I'm not sure that we really reduced the incidence of radiation necrosis. We saw radiation necrosis here. We saw less of it than in the trial of pembrolizumab monotherapy, but these were also different patients, different time. We saw more than we thought that we were going to see. It was 27%, I believe, which is fairly high still. We only gave the four doses of bevacizumab. Maybe to really prevent radiation necrosis, you have to continue to give the bevacizumab. That, too, needs to be tested. The reason that we gave the four doses of bevacizumab was simply because of the cost of the bevacizumab at the time. Dr. Davide Soldato Thank you very much for that comment on radionecrosis. And I really think that potentially this is a strategy, so continuing the bevacizumab, that really makes a lot of sense, especially considering that the tolerability of the regimen was really very, very good, and you didn't see any significant or serious adverse events related to bevacizumab. So just wondering if you could comment a little bit on the toxicities, whether you had anything unexpected. Dr. Harriet Kluger There was one patient who had a microperforation of a diverticulum, which was probably related to the bevacizumab. It was conservatively managed, and the patient did fine and actually remains alive now, many years later. We had one patient who had dehiscence of a previous wound. So there is some. We did not see any substantial hypertension, proteinuria, but we only gave the four doses. So it is possible that if you give it for longer, we would see some side effects. But still, relative to ipilimumab, it's very, very well tolerated. Dr. Davide Soldato Yeah, exactly. I think that the safety profile is really different when we compare the combination of ipilimumab/nivolumab with the pembrolizumab/bevacizumab. And as you said, this was a very small trial and probably we need additional results. But still, these results, in terms of tolerability and safety, I think they are very interesting. So one additional question that I think warrants a little bit of comment on your part is actually related to the presence of patients with BRAF mutation and, in general, to what you think would be the best course of treatment for these patients who present with the upfront brain metastases. So this, it's actually not completely related to the study, but I think that since patients with BRAF mutation were included, I think that this warrants a little bit of discussion on your part. Dr. Harriet Kluger So we really believe that long-term disease control, particularly in brain metastases, doesn't happen when you give BRAF/MEK inhibitors. You sometimes get long-term control if you've got oligometastatic disease in extracranial sites and if they've previously been treated with a lot of immune checkpoint inhibitors, which wasn't the case over here. So a patient who presents early in the course of the disease, regardless of their BRAF status, I do believe that between our studies and all the studies that have been done on immunotherapy earlier in the course of disease, we should withhold BRAF/MEK inhibitors unless they have overwhelming disease and we need immediate disease control, and then we switch them very quickly to immunotherapy. Can I also say something about the toxicity question from the bevacizumab? I have one more comment to make. I think it's important. We were very careful not to include patients who had overt hemorrhage from brain metastases. So melanoma brain metastases relative to other tumor types tend to bleed, and that was an exclusion criteria. We didn't see any bleeding that was attributable to the bevacizumab, but we don't know for sure that, if this is widely used, that that might not be a problem that's observed. So I would advise folks to use extreme caution and perhaps not use it outside of the setting of a clinical trial in patients with overt hemorrhage in the melanoma brain metastases. Dr. Davide Soldato Thank you very much. I think that one aspect that is really interesting in the trial is actually related to the fact that you collected a series of biomarkers, both circulating ones, but also some that were collected actually from the tissue. So just wondering if you could explain a little bit which type of biomarkers you evaluated and whether you saw any significant results that could suggest higher or lower efficacy of the combination. Dr. Harriet Kluger Thank you for that. So yes, the biomarker studies are fairly exploratory, and I want to emphasize that we don't have anything that's remotely useful in clinical practice at this juncture. But we did see an association between vessel density in the tumors and improved response to this regimen. So possibly those lesions that are more vascular are more fed by or driven by VEGF, and that could be the reason that there was improved response. We also saw that when there was less of an increase in circulating angiopoietin-2 levels, patients were more likely to respond. Whether or not that pans out in larger cohorts of patients remains to be determined. Dr. Davide Soldato Still, do you envision validation of these biomarkers in a potentially additional trial that will evaluate, again, the combination? Because I think that the signals were quite interesting, and they really make sense from a biological point of view, considering the mechanism of action of bevacizumab. So I think that, yeah, you're right, they are exploratory. But still, I think that there is very strong biological rationale. So really I wanted to congratulate you on including that specific part and on reporting it. And so the question is, really, do you envision validation of these biomarkers in larger cohorts? Dr. Harriet Kluger I would hope to see that, just as I'd like to see validation of the clinical results as well. The circulating biomarkers are very easy to do. It's a simple ELISA test. And the vessel density on the tumor is essentially CD34 staining and units per area of tumor. Also very simple to do. So I'd love to see that happen. Dr. Davide Soldato Do you think that considering the quality of the MRI that we are using right now, it would be possible to completely bypass even the evaluation on the tissue? Like, are we going in a direction where we can, at a certain point, say the amount of vessels that we see in these metastases is higher versus lower just based on MRI results? Dr. Harriet Kluger You gave me an outstanding idea for a follow-up study. I don't know whether you can measure the intensity of gadolinium as a surrogate, but certainly something worth asking our neuroradiology colleagues. Excellent idea. Thank you. Dr. Davide Soldato You're welcome. So just moving a step further, we spoke a lot about the validation of these results and the combination. And just wanted your idea on what do you think it would be more interesting to do: if designing a clinical trial that really compares pembrolizumab/bevacizumab with ipilimumab and nivolumab or going directly for the triplet. So we know that there has been some type of exploration of triplet combination in metastatic melanoma. So just your clinical impression: What would you do as an investigator? Dr. Harriet Kluger So it's under some discussion, actually. It's very difficult to compare drugs from different companies in an investigator-initiated trial. Perhaps our European colleagues can do that trial for us. In the United States, it's much harder, but it can be done through the cooperative groups, and we are actually having some discussions about that. I don't have the answer for you. It would be lovely to have a trial that compared the three drugs to ipi/nivo and to pembrolizumab/bevacizumab. So a three-arm trial. But remember, these are frontline melanoma patients. There aren't that many of them anymore like there used to be. So accrual will be hard, and we have to be practical. Dr. Davide Soldato Yeah, you're right. And in the discussion of the manuscript, you actually mentioned some other trials that are ongoing, especially one that is investigating the combination of pembro and lenvatinib, another one that is investigating the combination of nivolumab and relatlimab. So just wondering, do you think that the molecule in terms of VEGF inhibition, so bevacizumab versus lenvatinib, can really make a difference or is going to be just a mechanism of action? Of course, we don't have the results from this trial but just wondering if you could give us a general comment or your opinion on the topic. Dr. Harriet Kluger So that's a really great question. The trial of pembrolizumab and lenvatinib was our answer to the fact that bevacizumab is not manufactured by the same company as pembrolizumab, and we're trying to give a practical answer to our next study that might enable us to take this approach further. But it does turn out from our preclinical studies that bevacizumab and VEGF receptor inhibition aren't actually the same thing in terms of the effects on the blood-brain barrier or the perilesional tumor microenvironment in the brain. And these studies were done in mice and in in vitro models. Very different effects. The lenvatinib has stronger effect on the tumors themselves, the tumor cells themselves, than the bevacizumab, which has no effect whatsoever. But the lenvatinib doesn't appear to tighten up that blood-brain barrier. Dr. Davide Soldato Thank you. I think that's very interesting, and I think it's going to be interesting to see also results of these trials to actually improve and give more options to our patients in terms of different mechanism of action, different side effects. Because in the end, one thing that we discussed is that some combination may be useful in some specific clinical situation while others cannot be applicable, like, for example, an all immunotherapy-based combination. Just one final comment, because I think that we focused a lot on the intracranial response and progression-free survival. You briefly mentioned this but just wanted to reinforce the concept. Did you see any differences in terms of intracranial versus extracranial response for those patients who also had extracranial disease with the combination of pembro and bevacizumab? Dr. Harriet Kluger So the responses were almost always concordant. There were a couple of cases that might have had a body response and not an intracranial response and vice-versa, but the vast majority had concordant response or progression. We do believe that it's a biological phenomenon. The type of tumor that tends to go to the brain is going to be the type of tumor that will respond to whatever the regimen is that we're giving. In the previous trial also, we saw concordance of responses in the body and the brain. Dr. Davide Soldato Thank you very much. Just to highlight that really the combination is worth pursuing considering that there was not so much discordant responses, and the results, even in a phase 2 trial, were very, very promising. So thank you again, Dr. Kluger, for joining us today and giving us a little bit of insight into this very interesting trial. Dr. Harriet Kluger Thank you for having me. Dr. Davide Soldato So we appreciate you sharing more on your JCO article titled "Phase 2 Trial of Pembrolizumab in Combination with Bevacizumab for Untreated Melanoma Brain Metastases," which gave us the opportunity to discuss current treatment landscape in metastatic melanoma and future direction in research for melanoma brain metastasis. If you enjoy our show, please leave us a rating and review and be sure to come back for another episode. You can find all ASCO shows at asco.org/podcasts. The purpose of this podcast is to educate and to inform. This is not a substitute for professional medical care and is not intended for use in the diagnosis or treatment of individual conditions. Guests on this podcast express their own opinions, experience, and conclusions. Guest statements on the podcast do not express the opinions of ASCO. The mention of any product, service, organization, activity, or therapy should not be construed as an ASCO endorsement.
Got some shareable d-bag responses.
AT Parenting Survival Podcast: Parenting | Child Anxiety | Child OCD | Kids & Family
OCD thrives on urgency. The faster your child reacts to an intrusive thought, the more powerful OCD becomes. But what if your child learned to pause—even for a few seconds—before doing an OCD compulsion?In this episode, I'll walk you through how to introduce the concept of “delay” as a gentle, approachable first step in helping your child take back control. You'll learn how to teach it, what to expect, and why it works.Want to learn how to create an effective incentive plan? Listen to this podcast episode.Want more in-depth support?Register for my FREE video series: Survival Tools for Parents Raising Kids with Anxiety or OCD***This podcast episode is sponsored by NOCD. NOCD provides online OCD therapy in the US, UK, Australia and Canada. To schedule your free 15 minute consultation to see if NOCD is a right fit for you and your child, go tohttps://go.treatmyocd.com/at_parentingThis podcast is for informational purposes only and should not be used to replace the guidance of a qualified professional.Parents, do you need more support?
Join the conversation! Send Magic a text here!Today, we explore the effects of stress on our health and discuss both acute and chronic stress. Learn how cortisol, the primary stress hormone, impacts your body and discover practical ways to manage your stress healthily. From personal anecdotes of losing a friend and dealing with farm challenges to the benefits of mindful gardening and connecting with nature, this episode provides valuable insights into reducing stress and improving overall well-being. Tune in for actionable tips and a deeper understanding of how to create healthy responses when under stress.DoTERRA Wellness AdvocateAt Wholistic Natural Health Australia, we often recommend the use of high quality essential oils. Disclaimer: This post contains affiliate links. If you make a purchase, I may receive a commission at no extra cost to you.Support the showConnect with Magic:A Magical Life Podcast on Facebook: https://www.facebook.com/amagicallifepodcast/On Instagram: https://www.instagram.com/wholisticnaturalhealth/Online: https://wholisticnaturalhealth.com.auA Subito Media production
PodChatLive 178: Even more plantar fasciitis research (is it all really needed?) and individual responses to foot orthosesContact us: getinvolved@podchatlive.comLinks from this week's episode:The 6 best Asics running shoes for women, according to editors and podiatristsPlantar Fasciitis: An Autobiographical Case Report From the Perspective of an Athlete and PhysicianCan kinesio tape negatively affect the treatment by creating a hard floor in plantar fasciitis treatment? A randomized clinical trialTwo types of insoles design to influence running biomechanics in opposite directions and individual responses
In today's episode, supported by Replimune, we had the pleasure of speaking with Anna C. Pavlick, BSN, MSc, DO, MBA, about the use of RP1 plus nivolumab (Opdivo) for the treatment of patients with advanced melanoma. Dr Pavlick is a professor of medicine in the Division of Hematology & Medical Oncology at Weill Cornell Medicine in New York, New York; as well as the founding director of the Cutaneous Oncology Program at Weill Cornell Medicine and NewYork-Presbyterian. In our exclusive interview, Dr Pavlick discussed the rationale for investigating this combination in patients with advanced melanoma who have received prior immune checkpoint inhibition, key efficacy and safety findings from the phase 1/2 IGNYTE trial (NCT03767348), and where the future may be headed regarding the use of oncolytic viruses in melanoma.
In this episode of the Cult Vault Podcast, host Kacey speaks with Maya Badham, founder of Safeguarding Human and Animal Survivors of Sexual and Domestic Abuse (SAHSDA), about the intersection of animal cruelty and coercive control in domestic abuse. They explore how animals are used as tools of manipulation and control, the cultural contexts of animal abuse, and the importance of recognising these issues in the broader conversation about human rights and violence. Maya shares her unique career path and insights into the systemic issues surrounding animal and human abuse, emphasising the need for a coordinated response to these intertwined problems.www.crimecon.co.uk - code CULT for 10% off tickets! Home | SAHSDA Safeguarding human and animal survivors domestic abuse sexual abuseGet in Touch or Support: Patreon - patreon.com/thecultvaultCrimecon UK 2025 https://www.crimecon.co.uk - use code CULT for 10% off tickets!Instagram: https://www.instagram.com/cultvaultpod/Twitter: https://twitter.com/CultVaultPodReddit: https://www.reddit.com/user/Cult-VaultGmail: cultvaultpodcast@gmail.com
Jesus was crucified between two criminals—three crosses stood together on Calvary. Though the crosses appear similar, they represent three vastly different responses to Jesus and, ultimately, three distinct spiritual outcomes. How will you respond?Be part of what God is doing at Mount Holly! To learn more about our ministries, our pastor, and to plan your visit, click here: https://www.mountholly.orgBecause of your generosity, we're able to continue leading people into the life-changing presence of God. If you feel led to give, click here: https://www.mountholly.org/give
After a remarkable more than year-long journey exploring Paul's letter to the Ephesians, we're pausing to create space for your voice. This brief but important episode invites our listening community to reflect on the extensive series we've created together and share questions that remain as we prepare to conclude our study.Our exploration of Ephesians has traversed complex theological terrain, particularly when we encountered Chapter 5's challenging passages. These sections contain some of the most frequently misinterpreted verses in Christian history—texts that should nurture community but have often been weaponized instead. Throughout our series, we've sought to uncover the authentic Christ-centered message behind these words while acknowledging the harmful ways they've sometimes been understood.What questions linger for you? Which insights transformed your understanding? How has this journey through Ephesians resonated with your spiritual life? Whether you're a longtime listener or recently discovered our podcast, we welcome your voice. Visit patreon.com/ccseminary to submit an audio question or written comment by May 17, 2025. Selected questions will be addressed in upcoming episodes as we prepare to wrap up this profound journey through one of Christianity's most impactful letters. Your perspective matters to us—we can't wait to hear how Ephesians has spoken to you.Support the showThe Light in Every Thing is a podcast of The Seminary of The Christian Community in North America. Learn more about the Seminary and its offerings at our website. This podcast is supported by our growing Patreon community. To learn more, go to www.patreon.com/ccseminary. Thanks to Elliott Chamberlin who composed our theme music, “Seeking Together,” and the legacy of our original show-notes and patreon producer, Camilla Lake.
Glen Cole, the Assistant City Manager and Community Development Director for City of Rolling Meadows, Illinois joined the podcast to discuss intoxicating hemp regulation at the local government level. He shared how intoxicating hemp is different than recreational marijuana and the lack of state regulation related to intoxicating hemp. He also discussed how local regulation was implemented in Rolling Meadows. Host: Dan Bolin
Spiritual Responses: Key Points for a Christian Life In our journey of faith, how we respond spiritually to life's challenges, blessings, and questions deeply reflects our walk with Christ. Here are some core principles and key points to guide your spiritual responses: 1. Respond with Faith, Not Fear "God has not given us a spirit of fear, but of power, love, and a sound mind." – 2 Timothy 1:7 Faith trusts God even when the outcome is unclear. Fear reacts; faith responds. A spiritual response says, “I don't understand this, but I know God is still in control.” 2. Respond with Prayer First "Pray without ceasing." – 1 Thessalonians 5:17 Before reacting emotionally, go to God in prayer. Prayer aligns your heart with His will and gives you peace and clarity. 3. Respond with the Word of God "It is written..." – Matthew 4:4 Jesus answered temptation and attack by quoting Scripture. Know the Word, speak the Word, and let the Word guide your decisions and emotions. 4. Respond with Love and Grace "Let your speech always be with grace." – Colossians 4:6 Spiritual maturity is shown in how we handle others, especially in conflict. A harsh response feeds division, but a gracious one opens hearts. 5. Respond with Forgiveness "Forgive as the Lord forgave you." – Colossians 3:13 Forgiveness is a powerful spiritual act that frees both the offended and the offender. Holding onto offense hinders your growth; letting go invites healing. 6. Respond with Humility "God resists the proud, but gives grace to the humble." – James 4:6 Spiritual responses are rooted in humility—admitting we don't know everything, and we need God. Pride reacts to protect self-image; humility yields to God's shaping hand. 7. Respond with Praise and Gratitude "In everything give thanks..." – 1 Thessalonians 5:18 Even in trials, spiritual eyes look for God's hand and choose praise. Gratitude shifts the atmosphere and invites joy into the situation. 8. Respond with Obedience "If you love Me, keep My commandments." – John 14:15 A spiritual response isn't just emotional—it's obedient. Even when it's hard or unpopular, obedience brings blessing and growth.
Politicians are among those paying tribute to prominent businessman, author, and former politician Sir Bob Jones. The 85-year-old, who launched the New Zealand Party in the 1980s, has died peacefully at his Wellington home. Labour Leader Chris Hipkins described him as a colourful character, saying there's no doubt he impacted the political landscape, while Christopher Luxon described him as a legend, and paid tribute to him as a businessman. NZ Herald Political Editor Thomas Coughlan joined Heather du Plessis-Allan to break down the responses to Jones' death. LISTEN ABOVE See omnystudio.com/listener for privacy information.
Responses include: "the Google" . . . "strategery" . . . "deers" when they see more than one deer . . . and "it's not rocket surgery"
We’re constantly hearing conflicting advice about diets — one day something is good for you, the next day a new study says it’s not. With so much information, it’s no wonder many of us feel confused about what we should be eating to stay healthy. The reality is, there may not be a one-size-fits-all answer. What works well for one person might not work for another, and Dr Erin Clarke is a researcher with the Food and Nutrition Research Program at the Hunter Medical Research Institute, and she's is exploring how our genetic and metabolic differences can influence the way our bodies respond to food.See omnystudio.com/listener for privacy information.
In this episode of the Cannabis Cultivation and Science Podcast, we're joined by Dr. Michael Gutensohn, an expert in plant physiology and secondary metabolism, to explore the intricate relationship between environmental stress and the production of secondary metabolites in cannabis. We discuss how various abiotic stressors—such as light intensity, temperature fluctuations, and nutrient availability—can influence the biosynthesis of key phytochemicals, including cannabinoids, terpenes, and flavonoids. Dr. Gutensohn shares insights from his research on plant defense mechanisms, metabolic signaling pathways, and how growers might harness controlled stress to enhance both plant resilience and phytochemical output. Whether you're a cultivator aiming to fine-tune your grow environment or a scientist delving into cannabis metabolomics, this episode offers valuable, research-backed perspectives on optimizing secondary metabolite production through stress modulation.
Let's hear what you gotta say.
AP's Lisa Dwyer reports on a conservative activist's lawsuit againt Meta.
"Liberation Day created a crisis" but Brian Levitt says there's been some incremental improvement since the initial sell-off. He points to the bond market response on April 21st as a "stagflation fears" type of move, but noted the Trump Administration's 90-day tariff pause shortly after. On the consumer side, Brian adds there's concerns about where prices are going and that the market will look for "better news now."======== Schwab Network ========Empowering every investor and trader, every market day.Subscribe to the Market Minute newsletter - https://schwabnetwork.com/subscribeDownload the iOS app - https://apps.apple.com/us/app/schwab-network/id1460719185Download the Amazon Fire Tv App - https://www.amazon.com/TD-Ameritrade-Network/dp/B07KRD76C7Watch on Sling - https://watch.sling.com/1/asset/191928615bd8d47686f94682aefaa007/watchWatch on Vizio - https://www.vizio.com/en/watchfreeplus-exploreWatch on DistroTV - https://www.distro.tv/live/schwab-network/Follow us on X – / schwabnetwork Follow us on Facebook – / schwabnetwork Follow us on LinkedIn - / schwab-network About Schwab Network - https://schwabnetwork.com/about
In his sermon, Marcus emphasizes the importance of taking next steps in our relationship with Jesus, especially following the powerful move of God during Easter. He highlights the six practices early disciples devoted themselves to: groups, serving, giving, rhythms, outreach, and worship. Marcus encourages the church to embrace these practices to experience the abundant life that comes from following Jesus as apprentices. He also introduces a redesigned app that will help individuals identify and take actionable steps in their discipleship journey.
Speaker: Pastor Bruce Burkett Title: Responses To The ResurrectionText: Matthew 28:1-15
Lone Star Cowboy Church, founded in 2000, is committed to developing Christ-followers through "Reaching, Teaching, Discipling." People are God's greatest treasure therefore everyone is welcome, join us on campus, or online as we learn and grow together. lonestar.tv www.facebook.com/lonestar.tv/ www.instagram.com/lonestartv/
Easter Sunday | John 9:19-25 | Jake Hering
El Salvador is receiving prisoners snatched by the US federal government. The Supreme Court has ordered the Trump administration to "facilitate" the return of one prisoner. Ilya Somin details some of the more troubling aspects of this struggle. We spoke April 11, 2025. Hosted on Acast. See acast.com/privacy for more information.
Steve Ward returns to the podcast to talk about a paper he recently published with co-author Teresa Grimes, titled, "50 Practical Ways to Alter the Relative Efficiencies of Behaviors." In this conversation, we review the highlights of this paper, and discuss things like The Matching Law, making desired behavior more efficient in generating reinforcement, making problem behaviors less efficient, and how altering reinforcement parameters like delay, magnitude, and schedules can enhance learner progress. We also talk about the work that Steve does with his company, Whole Child Consulting, as well as a Q & A he will be doing on this topic that's coming up on April 23rd, 2025. Steve is the author of Teaching Good Learner Repertoires, What You Need To Know About Motivation And Teaching Games: An In-Depth Analysis, and other popular texts relevant to Behavior Analysts working in a variety of settings. If you'd like to work with Steve or find supplementary materials on the things he likes to talk about, check out his website, Whole Child Consulting. Resources discussed in this podcast: Ward and Grimes (2025). 50 Practical Ways to Alter the Relative Efficiencies of Behaviors. Ward, Parker, and Perdikaris (2016). Task as Reinforcer: a Reactive Alternative to Traditional Forms of Escape Extinction. Perone (2003). The Negative Effects of Positive Reinforcement. Steve's earlier appearances on the BOP in Session 111 and Session 187. Anxiety? ABA has something for that! (Steve's Behavior University webinar, use promo code PODCAST at checkout to save $$$). Please note that we had some internet disruptions during our recording but I don't think they detracted from the overall intelligibility of the conversation. This podcast is brought to you by: Frontera. Consider taking a demo of Frontera's Assessment Builder and see how the ethical application of AI technologies can help you serve clients and save you time! Your first assessment report is free. And if you use code BOP25 you'll get an additional five assessments for just $100. So head to fronterahealth.com to check it out! CEUs from Behavioral Observations. Learn from your favorite podcast guests while you're commuting, walking the dog, or whatever else you do while listening to podcasts. New events are being added all the time, so check them out here. The Behavioral Toolbox. Check out our courses for school-based and other behavioral professionals, including our newest one, Motivational Interviewing: Getting Educator Buy-In. Behavior University. Their mission is to provide university quality professional development for the busy Behavior Analyst. Learn about their CEU offerings, including their 8-hour Supervision Course, as well as their RBT offerings over at behavioruniversity.com/observations. Don't forget to use the coupon code, PODCAST to save at checkout!
Take our free English-level quiz here to find out what your current English level is. Do you love All Ears English? Try our other podcasts here: Business English Podcast: Improve your Business English with 3 episodes per week, featuring Lindsay, Michelle, and Aubrey IELTS Energy Podcast: Learn IELTS from a former Examiner and achieve your Band 7 or higher, featuring Jessica Beck and Aubrey Carter Visit our website here or https://lnk.to/website-sn Send your English question or episode topic idea to support@allearsenglish.com In charge of hiring for your company? Go to Indeed and support our show by saying you heard about Indeed on this podcast. Terms and conditions apply. Hiring? Indeed is all you need. Go to https://www.indeed.com/aee Learn more about your ad choices. Visit podcastchoices.com/adchoices
Strawberry Letter Subject for Tuesday, April 8th, 2025: "I Slipped Up and Went Back For More "Dear Steve and Shirley, I’m married to a great man that looked good and had everything going for him, except in the bedroom. I told myself that sex wasn’t everything and I managed to make it for 3 years without cheating. Up until our wedding, I was sleeping with my daughter’s father..." Listen to Steve & Shirley's Responses!See omnystudio.com/listener for privacy information.
© 2020-2025 Ivy Podcast Discovery LLC
